X-trant is used in the palliative treatment of metastatic/progressive carcinoma of prostate, and ensures complete hormonal as well as cytotoxic control. While ensuring reduction in the intensity of pain, and absence of hepatic and renal toxicity, X-trant is a unique anti-tumor agent and its usage would improve performance status of patients suffering from prostate cancer.
The medicine is also useful in patients with limited bone marrow reserve. X-trant has a dual mode of action. Structurally, X-trant (estramustine) would be a phosphorylated combination of estradiol and mechlorethamine (nitrogen mustard).
The intact molecule acts as an antimitotic agent. It binds to a protein present in the tumor tissue which results in an accumulation of the drug at the target site. NATCO's X-trant ensures not only availability of the drug, but also at an affordable price.
Note: Xtrant is a prescription drug and should be used under proper medical guidance and advice.
Do not share the medicine with others, since they may be suffering from a problem that is not effectively treated by this drug.